Important Reminder for Ultragenyx Pharmaceutical Investors: Securities Class Action Deadline Approaches

Investor Alert: Securities Class Action Against Ultragenyx Pharmaceutical

In a significant announcement, Faruqi & Faruqi, LLP, a renowned national securities law firm, has alerted investors regarding a potential class action lawsuit against Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE). The firm is currently investigating claims of misconduct that could have adversely affected shareholders.

Context of the Investigation

The investigation centers on allegations that Ultragenyx and its executives made false or misleading statements concerning the company’s clinical studies involving setrusumab, a treatment for Osteogenesis Imperfecta (OI). It has come to light that the company may have failed to provide crucial information regarding the effectiveness of this drug during their Phase III Orbit study.

Faruqi & Faruqi emphasizes the importance of immediate action. Investors who acquired shares between August 3, 2023, and December 26, 2025, have until April 6, 2026, to seek the role of lead plaintiff in the case. Being a lead plaintiff allows shareholders to have a say in the litigation’s direction and strategy.

Unfolding Events

The serious allegations began garnering attention after Ultragenyx disclosed that its Phase III Orbit study did not yield statistically significant results on July 9, 2025. Following this revelation, the stock price plummeted by over 25%. Further compounding the investors' worries, on December 29, 2025, the company announced that both the Orbit and Cosmic studies failed to meet critical endpoints, leading to an additional drop in share price by more than 42%.

These statements have led many to believe that Ultragenyx may have misled investors regarding the potential of their treatment, causing significant financial distress. The consequences of these misleading communications have been far-reaching, prompting legal scrutiny and rising concerns among investors.

How Investors Can Engage

Faruqi & Faruqi encourages investors affected by these revelations to contact them for a detailed discussion about their legal rights and options. Interested shareholders can reach out to partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

The firm reassures that anyone with relevant information regarding Ultragenyx's conduct is welcome to step forward. This includes former employees, whistleblowers, and other stakeholders who may provide valuable context to the ongoing investigation.

Conclusion

The impending deadline underscores the importance of timely action on the part of affected investors. Engaging in such class action lawsuits can serve to protect shareholder interests and ensure accountability among corporate executives. As the deadline approaches, the urgency for affected Ultragenyx shareholders grows. Visit www.faruqilaw.com/RARE for additional details on how to proceed.

Stay informed and vigilant as developments in this matter unfold. Legal avenues are available for investors seeking justice in light of these troubling allegations against Ultragenyx Pharmaceutical.